+

WO2004016738A3 - Method and composition for treating and preventing hepatitis c infection - Google Patents

Method and composition for treating and preventing hepatitis c infection Download PDF

Info

Publication number
WO2004016738A3
WO2004016738A3 PCT/US2003/022956 US0322956W WO2004016738A3 WO 2004016738 A3 WO2004016738 A3 WO 2004016738A3 US 0322956 W US0322956 W US 0322956W WO 2004016738 A3 WO2004016738 A3 WO 2004016738A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
infection
patient
composition
hcv
Prior art date
Application number
PCT/US2003/022956
Other languages
French (fr)
Other versions
WO2004016738A2 (en
Inventor
Scott Morham
Kenton Zavitz
Adrian Hobden
Original Assignee
Myriad Genetics Inc
Scott Morham
Kenton Zavitz
Adrian Hobden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc, Scott Morham, Kenton Zavitz, Adrian Hobden filed Critical Myriad Genetics Inc
Priority to AU2003256678A priority Critical patent/AU2003256678A1/en
Publication of WO2004016738A2 publication Critical patent/WO2004016738A2/en
Publication of WO2004016738A3 publication Critical patent/WO2004016738A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods for preventing and treating HCV infection and symptoms thereof by introducing cells displaying a HCV altered budding phenotype into a patient, or by administering to a patient nucleic acids, polypeptides and small organic compounds to cause the formation of cells displaying a HCV altered budding phenotype in the body of the patient.
PCT/US2003/022956 2002-07-19 2003-07-21 Method and composition for treating and preventing hepatitis c infection WO2004016738A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003256678A AU2003256678A1 (en) 2002-07-19 2003-07-21 Method and composition for treating and preventing hepatitis c infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39726702P 2002-07-19 2002-07-19
US60/397,267 2002-07-19

Publications (2)

Publication Number Publication Date
WO2004016738A2 WO2004016738A2 (en) 2004-02-26
WO2004016738A3 true WO2004016738A3 (en) 2004-06-17

Family

ID=31888187

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/022956 WO2004016738A2 (en) 2002-07-19 2003-07-21 Method and composition for treating and preventing hepatitis c infection

Country Status (2)

Country Link
AU (1) AU2003256678A1 (en)
WO (1) WO2004016738A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006011686A1 (en) * 2004-07-30 2006-02-02 Japan Tobacco Inc. Method of screening compound preventing cells from infection with hepatitis c virus (hcv)
KR100734525B1 (en) * 2005-05-27 2007-07-03 크레아젠 주식회사 Effectively measuring cytotoxic T lymphocyte activity in humans and non-familial animals
CN100586474C (en) * 2006-12-28 2010-02-03 北京炎黄麒麟生物技术开发有限公司 Medicine composition, kit and application thereof
CN108707190B (en) * 2018-04-18 2021-07-13 中国科学院武汉病毒研究所 Fidelity mutants of swine fever virus NS5B protein and their applications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228576B1 (en) * 1997-12-11 2001-05-08 Smithkline Beecham Corporation Hepatitis C virus NS5B truncated protein and methods thereof to identify antiviral compounds
US6461845B1 (en) * 1995-09-27 2002-10-08 Emory University Recombinant hepatitis C virus RNA replicase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461845B1 (en) * 1995-09-27 2002-10-08 Emory University Recombinant hepatitis C virus RNA replicase
US6228576B1 (en) * 1997-12-11 2001-05-08 Smithkline Beecham Corporation Hepatitis C virus NS5B truncated protein and methods thereof to identify antiviral compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EGGER D. ET AL.: "Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex", J. VIROL., vol. 76, no. 12, June 2002 (2002-06-01), pages 5974 - 5984, XP002973294 *
KOLYKHALOV A.A. ET AL.: "Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo", J. VIROL., vol. 74, no. 4, February 2000 (2000-02-01), pages 2046 - 2051, XP002973293 *

Also Published As

Publication number Publication date
AU2003256678A1 (en) 2004-03-03
WO2004016738A2 (en) 2004-02-26
AU2003256678A8 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
WO2002058638A3 (en) Serpin drugs for treatment of hiv infection and method of use thereof
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
WO2003087092A3 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
WO2005084295A3 (en) Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
WO2004043339A3 (en) Substituted cycloalkyl p1' hepatitis c virus inhibitors
WO2005037214A3 (en) Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
EP1441720B8 (en) Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
NO20100093L (en) Peptidomimetic protease inhibitors
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
WO2003089619A3 (en) Placental derived stem cells and uses thereof
WO2002060926A3 (en) Hepatitis c tripeptide inhibitors
HK1103363A1 (en) Treatment of glycogen storage diseases type ii ii
NO20061426L (en) Inhibitors of serine proteases, especially HCV NS3-NS4A protease
WO2005042020A3 (en) Combinations for hcv treatment
WO2005063734A3 (en) Substituted thiophenes
NO20071912L (en) Donepezil salts suitable for the preparation of pharmaceutical compositions.
WO2005002526A3 (en) Method and compositions for treatment of viral infections
WO2001023421A3 (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
WO2003030886A3 (en) Allylamides useful in the treatment of alzheimer's disease
WO2003015708A3 (en) Composition and method for treating hiv infection
UA91677C2 (en) Macrocyclic compounds as inhibitors of hcv replication
WO2003059262A3 (en) Method and composition for treating and preventing hiv infection and aids
WO2004009032A3 (en) Method and composition for treating and preventing hepatitis b infection and symptoms thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载